The IMA Group (IMA), a leading technology-enabled provider of clinical trials and medical and psychological screening and evaluation services, announced that industry veteran Dana Poff would lead IMA's Clinical Research Division as Executive Vice President.
IMA Clinical Research is a flexible, full-service clinical trial network consisting of geographically diverse clinical trial sites and over 150 satellite sites that conduct site-based, hybrid and decentralized clinical trials.
Poff, a high-profile leader in the clinical trial space, brings over 30 years of clinical trial experience to IMA, having held senior-level positions overseeing global project management, strategic alliances and clinical operations for ICON, plc.
"I'm excited to join the team at IMA Clinical Research," said Poff. "Together, we'll continue with the impressive growth and scale of the company's unique delivery model. By leveraging dedicated sites, staff, physicians, and clinics, we can help facilitate the advancement of drug development and bring innovative treatments to patients."
Dr. Mark Weinberger, President and CEO of the IMA Group, stated, "We are incredibly pleased to have Dana lead our clinical research division. Her world-class experience conducting clinical trials will accelerate the substantial growth and expansion in footprint and diversity our clinical research division has enjoyed over the last several years."
The company also reported that Michael Minor, who has played a vital role in fueling the division's growth, will remain an Executive Advisor to the IMA Group's highly experienced clinical research team (https://imaresearch.com/about/leadership/).
The IMA Group is a leading technology-enabled provider of clinical trial and medical and psychological screening and evaluation services. IMA Clinical Research, a division of The IMA Group, is a physician-founded network of comprehensive clinical research sites specializing in Phase II-IV clinical trials in multiple therapeutic areas. IMA Clinical Research conducts site-based, hybrid and fully decentralized clinical trials that support the development of safe and effective new treatments. For more information, visit https://imaresearch.com/or https://theimagroup.com/.